Patients with COVID-19 frequently develop reduced insulin sensitivity due to SARS-CoV-2–induced β-cell damage, often necessitating increased insulin dosages, particularly during febrile episodes when metabolic demand is heightened [59]. The gene discussed is INS; the disease is COVID-19.